HOME >> BIOLOGY >> NEWS
Weill Cornell pharmacologist receives prestigious NIH MERIT Award

$2.5 million grant supports research into potential pharmaceutical targets for treating vascular complications of diabetes

NEW YORK (May 21, 2007) -- A leading authority and pioneer in the pharmacology of the signaling molecule nitric oxide (NO), Weill Cornell Medical College scientist Dr. Steven S. Gross has been selected by the National Heart, Lung, and Blood Institute (NHLBI) to receive a 2007 National Institutes of Health (NIH) Method to Extend Research in Time (MERIT) Award, representing the fourth year the College has been selected for the prestigious honor.

This year's $2.5 million five-year research grant will provide long-term support for research aimed at furthering understanding of the NO-related trigger for vascular complications of diabetes and developing novel pharmaceutical approaches for ameliorating the condition.

Dr. Gross is professor of pharmacology, director of the mass spectrometry core facility and principal investigator on an NIH grant that supports the training of Ph.D. candidates in the Graduate School Program in Pharmacology at Weill Cornell Medical College.

"We are extremely grateful for the NIH's continued support for our translational research efforts," says Dr. Antonio M. Gotto Jr., the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College. "Dr. Gross is highly deserving of this honor. His research has uncovered a wealth of information about the important role of nitric oxide in the body. This work, which has laid the groundwork for treatments of numerous disease conditions that have been attributed to nitric oxide excess or insufficiency, is currently focused on new approaches for one of the most painful complications of diabetes."

Beginning in the late 1980s, Dr. Gross and colleagues made several key discoveries about nitric oxide. Working with Dr. Roberto Levi and colleagues at Weill Cornell, Dr. Gross was a member of the first group to administer a selective inh
'"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
21-May-2007


Page: 1 2 3 4

Related biology news :

1. Weill Cornell team identifies potential new cancer drug target
2. Stem cell research at Weill Cornell, The Rockefeller University, and Sloan-Kettering
3. Weill Cornell team develops fast-acting anthrax vaccine
4. Cornell scientists link E. coli bacteria to Crohns disease
5. Methodist, University of Houston, Cornell combine biomedical imaging expertise
6. Cornell lab confirms deadly fish virus spreading to new species
7. NSF awards $3.3 million grant to Cornell to bolster the percentage of women faculty members
8. Cornell researchers find serious fish virus in Northeast for first time
9. Cornell finds natural selection in humans
10. Northeast Sun Grant Institute at Cornell spurs green revolution
11. Cornell graduate student named 2005 AIBS Emerging Public Policy Leader

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/25/2019)... ... September 25, 2019 , ... LeadingBiotech ... and dialogue, today announces its inaugural South CEO conference to be ... , Co-produced by Tulane University, this invitation-only meeting convenes biopharma executives to ...
(Date:9/24/2019)... ... September 24, 2019 , ... ... interactions for accelerated drug development, announced today that it has raised $2.8M from ... OS Fund and also includes AME Cloud Ventures, Boom Capital, Madrona Venture Group, ...
(Date:9/17/2019)... ... September 17, 2019 , ... Last week, Blackrock Microsystems, ... from the Medical University of Warsaw, met at the Presidential Palace of the ... a neuroprosthetic system as part of an initiative called "Startups in the Palace ...
Breaking Biology News(10 mins):
(Date:9/24/2019)... (PRWEB) , ... September 24, 2019 , ... In the ... for research led by faculty at South Dakota School of Mines & Technology ... tiny microbes that attach to surfaces to form a slimy and yet strong layer ...
(Date:9/17/2019)... ... September 17, 2019 , ... Geneticure, Inc., a ... announces today that the U.S. Patent and Trademark Office (USPTO) and European Patent ... drug class recommendations for hypertension treatment. , The patent applies to Geneticure’s ...
(Date:9/17/2019)... ... 16, 2019 , ... MyBioGate Global Healthcare Innovation Competition Boston ... Boston, a forum organized by MyBioGate, Inc. and CUBIO Innovation Center that promotes ... process of evaluation, twelve companies out of over 200 applications were selected to ...
(Date:9/11/2019)... ... September 10, 2019 , ... ... for drugs, biologics, gene therapies, and consumer health products, today announced that Alex ... at the Bausparkasse Schwäbisch Hall AG, Schwabisch Hall, Germany, on Sept. 18-19, 2019. ...
Breaking Biology Technology:
Cached News: